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Abstract
Background: Acute lung injury (ALI) is an example of a critical care syndrome with limited treatment options once
the condition is fully established. Despite improved understanding of pathophysiology of ALI, the clinical impact
has been limited to improvements in supportive treatment. On the other hand, little has been done on the
prevention of ALI. Olmsted County, MN, geographically isolated from other urban areas offers the opportunity to
study clinical pathogenesis of ALI in a search for potential prevention targets.
Methods/Design: In this population-based observational cohort study, the investigators identify patients at high
risk of ALI using the prediction model applied within the first six hours of hospital admission. Using a validated
system-wide electronic surveillance, Olmsted County patients at risk are followed until ALI, death or hospital
discharge. Detailed in-hospital (second hit) exposures and meaningful short and long term outcomes (quality-
adjusted survival) are compared between ALI cases and high risk controls matched by age, gender and probability
of developing ALI. Time sensitive biospecimens are collected for collaborative research studies. Nested case control
comparison of 500 patients who developed ALI with 500 matched controls will provide an adequate power to
determine significant differences in common hospital exposures and outcomes between the two groups.
Discussion: This population-based observational cohort study will identify patients at high risk early in the course
of disease, the burden of ALI in the community, and the potential targets for future prevention trials.
Background
Acute lung injury (ALI) and its more severe form Acute
respiratory distress syndrome (ARDS) are common and
devastating complications after acute illness or injury
with high morbidity and mortality, long term decrease
in quality of life, and enormous costs related to inten-
sive care and rehabilitation [1]. ALI is an example of a
critical care syndrome with limited treatment options
once the condition is fully established. Despite improved
understanding of the pathophysiology of ALI, the clini-
cal impact has been limited to improvements in suppor-
tive treatment [2,3]. Surprisingly little research has been
done on the prevention of ALI. Preclinical studies sup-
port a “two hit” model of development of ALI whereby
different exposures modify the expression of ALI in sus-
ceptible host [4]. Preliminary data suggest that ALI is
rarely present at the time of hospital admission but
develops over a period of hours to days in subsets of
patients with predisposing conditions such as pneumo-
nia, sepsis, trauma, shock and corresponding medical
and surgical interventions [5-12]. To this extent, ALI
may be viewed as potentially preventable hospital com-
plication similar to stress ulcer bleeding, venous throm-
boembolism or nosocomial infections. Previous clinical
studies enrolled patients after ICU admission, often with
already established ALI, beyond the window of meaning-
ful mechanistic studies and potential prevention strate-
gies [13-15]. Not surprisingly, many treatments targeting
the mechanisms identified in preclinical studies have
failed to improve patient outcomes despite compelling
preclinical data [16-19]. It is likely that, inadequate and
delayed recognition of patients at risk and the subsequent
development of the full blown syndrome have obscured
the therapeutic window. ALI usually develops during the
first hours of ICU admission, and often is the very reason
for ICU admission. On the other hand, the majority of
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and they may never been admitted to the ICU making
the enrollment of unselected patients into ALI preven-
tion studies neither feasible nor efficient [12,10]. A mean-
ingful approach to ALI prevention therefore ought to be
based on identifying patients at risk earlier than what is
currently done (at the time of hospital admission, rather
than ICU admission, Figure 1) [10].
Methods/Design
In this population based cohort study the investigators
will identify patients at risk early in the course of the
disease and before the development of ALI (at the time
of hospital admission). Detailed in-hospital exposures,
short and long term outcomes will be compared
between patients at high risk who do and do not
develop ALI. (Figure 2)
Inclusion Criteria
Olmsted County residents more than 18 years of age
a d m i t t e dt ot h et w oM a y oC l i n i cR o c h e s t e rh o s p i t a l s
with one or more of the ALI predisposing conditions
(sepsis, pneumonia, aspiration, pancreatitis, shock, high
risk trauma, and high risk surgery). (Table 1) Exclusion
criteria are listed in Table 2. Institutional review board
has approved the study protocol.
System-wide electronic surveillance
Electronic medical records (EMR) facilitate early recog-
nition of specific study criteria using Boolean combina-
tions of clinical variables and natural language
processing. In this study we are planning to use a custo-
mized, integrative relational research database that
contains a near-real time (15 minutes delay) copy of
electronic medical records (ICU DataMart). To identify
Olmsted County residents at risk admitted to the two
Mayo Clinic hospitals, ICU DataMart uses 9-digit ZIP
code and a specific nursing unit codes and generates e-
mail and/or pager alert within 15 minutes from the time
the patient is assigned a bed in the receiving unit.
Patients admitted for labor and delivery, specific proce-
dures (cardiac catheterization), cardiac telemetry, coron-
ary care unit, low risk elective surgeries and children are
excluded from the alerts. Screening for ALI develop-
ment is performed by previously validated ARDS “snif-
fer” [20,21]. The electronic alert is triggered by the
following combination of observations: 1) qualifying
arterial blood gas analysis: the ratio of partial pressure
of oxygen to inspired oxygen concentration (PaO2/FIO2)
<300 and 2) qualifying chest radiograph report: free text
Boolean query containing trigger words: ("bilateral”
AND “infiltrate”)O R“edema” The ARDS sniffer
demonstrated excellent negative predictive value (0.99,
95% CI 0.98 to 1.00) [20]. ARDS-sniffer has been con-
tinuously running since December of 2005 allowing for
prospective identification of ALI cases. Access to the
database is accomplished through password protected
open database connectivity (ODBC) using JMP and SAS
statistical software (SAS Institute Inc., Cary, NC, USA).
Early identification of patients at risk of ALI (lung injury
prediction score - LIPS)
To facilitate enrollment of patients into mechanistic and
outcome studies as well as future ALI prevention trials,
we have recently developed an ALI prediction model
(Lung Injury Prediction Score: LIPS, Table 1) [22]. LIPS
Figure 1 Proposed “two hit” model of ALI development: the window of opportunity exists for the potential ALI prevention strategies.
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Table 1 Predisposing conditions and modifiers available before or within six hours after hospital admission used to
calculate the lung injury prediction score (LIPS): [22].
Risk factors Measurement Definition
Pneumonia Yes/No Consensus Conference [24]
Sepsis Yes/No, severe SCCM-ACCP definition [25]
Pancreatitis Yes/No Practice guidelines in acute pancreatitis [26]
Aspiration (pre-admission) Yes/No Inhalation of food or gastric contents [27]
High risk trauma Lung contusion, smoke inhalation, near-drowning,
multiple bone, brain injury
From Derdak [28]
High risk surgery Aortic vascular, spine, thoracic, acute abdomen,
emergency
From Arozullah et al [29,30]
Risk Modifiers
Alcohol use Yes/No, amount (# of drinks a week) More than 2 drinks per day or a history of alcohol-related
illness or admission [31,32]
Smoking Never/former/current/# of pack-years Substance Abuse and Mental Health
Diabetes mellitus* Yes/No Diabetes care 2009 [33]
Interstitial lung disease Yes/No ATS-ERS Consensus classification of IIP [34]
Chemotherapy Yes/No Custom, cancer chemotherapeutic drugs during the 6
months prior to hospitalization
Tachypnea (respiratory rate>30), Based on the worst value during the first 6 hours
High inspired oxygen
concentration (FIO2>0.35)
Based on the worst value during the first 6 hours
Hypoalbuminemia Serum albumin <3.5 g/dL, the absence of measurement
considered normal
*Only if sepsis
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the time of, and before, hospital admission. Risk factors
for ALI that were identified in at least two previous stu-
dies were used in model development. LIPS points were
determined based on parameter estimates from the
logistic regression model, taking into consideration
results from our previous studies. The model accurately
discriminated between the patients who did and did not
develop ALI with an area under the receiver operating
curve of 0.85 (95% CI 0.80 to 0.89) [22].
Twice daily (7 AM and 5 PM, Monday-Saturday)
trained study coordinators review syndrome surveillance
alerts of new Olmsted County admissions and apply LIPS
points to patients who fulfill the inclusion criteria accord-
ing to LIPS score sheet. ODBC MS Access database tool
is used for the collection of individual patient data in a
systematic way. The database automatically links MS
Access to ICU Datamart server and imports new patients
from ICU Datamart to the LIPS database. The database
also links automatically to the IRB research authorization
web site identifying the patients that have approved the
use of their medical data for research.
Validation of the primary outcome (ALI)
Primary outcome is the development of ALI at any time
during the hospital stay. Trained investigators review
each ARDS sniffer alert (see above) and confirm the
presence or absence of ALI according to the standard
definition based on the American-European consensus
conference [21]. The absence of left atrial hypertension
as the principal explanation for pulmonary edema is
confirmed by integrated clinical evaluation based on the
following:
￿ Echocardiography (E/E’<15, EF>45)
￿ Pulmonary artery occlusion pressure (PAOP) ≤ 18
cm H2O
￿ Central venous pressure (CVP < 15) cm H2O
(higher cutoff in pulmonary hypertension)
￿ History of congestive heart failure/cardiogenic pul-
monary edema
￿ Brain natriuretic peptide (BNP) <250 pg/mL
(higher cutoff in renal failure)
￿ Response to preload reduction: brisk (hours)
response to diuretics and/or positive pressure venti-
lation favors hydrostatic edema
This process yielded good interobserver agreement for
differentiation between ALI and hydrostatic edema
(Kappa value 0.83 in the most recent retrospective
Olmsted county study) [10].
Identification of in-hospital exposures
To identify candidate interventions for ALI prevention,
we are planning to identify hospital acquired (2
nd hit)
environmental exposures that may modify the risk of
ALI and its consequences in high risk subgroups of
patients residing in the Olmsted County community
identified by the LIPS model. Timing and intensity of
environmental exposures (Table 3) will be determined
by the review of monitoring logs, nursing and physician
interventions in the EMR by trained study coordinators
blinded to ALI status. Only the exposures occurring
before development of the ALI in cases and during the
corresponding period of time in controls will be ana-
lyzed as modifiers of ALI development.
Bio specimen collection and storage for collaborative
genomic and biomarker studies
Having identified both a robust phenotype and a
detailed account of potentially important environmental
exposures we will collect time sensitive peripheral blood
samples for collaborative genome-wide association and
plasma biomarker studies. Waste blood samples col-
lected for routine clinical care will be collected at base-
line (hospital admission), after 24 and 48 hours, and on
the day of development of ALI (if outside these 3 time
points).
Attributable burden of ALI
To prioritize future ALI prevention strategies, we are
planning to determine the attributable burden of ALI in
the Olmsted County community by quantifying patient-
centered outcomes attributable to this condition. The
essential patient-centered outcomes (unadjusted and
quality-adjusted survival, neurocognitive, neuropsycholo-
gic and neuromuscular complications, functional out-
come, and quality of life) will be compared between
patients who do and do not develop ALI. The instru-
ments we have chosen to evaluate our patients are listed
in Table 4. These instruments were selected to assess
Table 2 Exclusion criteria.
Exclusion Criteria Justification
Acute lung injury or pulmonary
edema already present at the time of
hospital admission
Unable to assess for
development of outcome of
interest
Admitted for comfort or hospice care
only
Missing predictor and outcome
variables
Denied the use of medical records for
research (~5%)
Self explanatory
Patients admitted for cardiac
telemetry, coronary care unit, low risk
elective surgeries, labor and delivery
Very low risk of outcome of
interest
Children Different risk factors and
outcome
Hospital readmission Complexity of analysis
Hospital transfer Exposure to health care
interventions
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jeopardizing the ability and willingness of the patients to
provide data. Specifically these instruments will give a
general measure of Quality of life (QOL) (SF12), along
with measures of physical, cognitive and psychological
functioning and would provide a comprehensive picture
of our patients’ experience. Baseline (premorbid) func-
tional status and QOL will be determined by in-hospital
retrospective survey of the patients or their surrogates.
After obtaining informed consent trained study coordi-
nators establish if the patient is competent to complete
the entire questionnaire by administering the mini men-
tal test. If patient is deemed incompetent or too ill to
complete the survey a surrogate will be identified to
help fill the questionnaires. Follow-up contact informa-
tion will be obtained and the patients or their surrogate
Table 3 Hospital (second hit) exposures that may modify the development of ALI in high risk patients.
Variable Measurements
A. Exposures associated with development of ALI in preliminary studies
Treatment of
infection
Antibiotics Time to administration of adequate antibiotics
Source control List source, time to source control
Shock resuscitation Early goal directed resuscitation Time to completion of goal directed resuscitation




Inspired oxygen concentration (FIO2) AUC, mean, median and maximum value during the exposure time of
interest
Ventilator tidal volumes (mL/kg predicted weight) AUC, mean, median and maximum value during the exposure time of
interest
Peak and plateau airway pressures (cm H2O) AUC, mean, median and maximum value during the exposure time of
interest
PEEP (cm H2O) 5-10 (reference), <5, >10 cm H2O
Respiratory rate AUC, mean, median and maximum value during the exposure time of
interest
Medications Amiodarone Cumulative dose during the exposure time of interest
Chemotherapy Cumulative dose during the exposure time of interest
Other
complications
Aspiration (in hospital) Inhalation of food or gastric contents
Medical or surgical misadventures List complication (ICD-9 code E870-E879.9)
B. Additional biologically plausible hospital exposures - exploratory analysis
Mechanism Variable Measurements
Inflammation Corticosteroids, inhaled and systemic Cumulative dose during the exposure time
Statins Cumulative dose during the exposure time
Insulin Cumulative dose during the exposure time
ACE inhibitor Cumulative dose during the exposure time
Oxidative stress Antioxidants: N-Acetylcysteine, vitamin C, Vit E, Ω 3
fatty acids
Cumulative dose during the exposure time
Coagulation Anticoagulants (heparin, coumadin) Cumulative dose during the exposure time
Antiplatelet agents (aspirin, clopidogrel) Cumulative dose during the exposure time
Aspiration Head of the bed position Above horizontal
Gastric tube feeding Cumulative dose during the exposure time
Sedative agents Cumulative dose during the exposure time
Narcotics Cumulative dose during the exposure time
Antipsychotics Cumulative dose during the exposure time
Gastric acid agents (H2 blockers, PPIs) Cumulative dose during the exposure time
Metabolic IV fluid (saline, Ringer, albumin) Cumulative dose during the exposure time
Furosemide Cumulative dose during the exposure time
Beta agonists, inhaled and systemic Cumulative dose during the exposure time
Laboratory findings: albumin, pH, glucose,
osmolarity
The worst value during the exposure time of interest
AUC - area under the curve, PEEP - positive end expiratory pressure
PPI - proton pump inhibitor
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contacted by telephone six month after index
hospitalization.
Strategies for subject retention
We selected survey instruments to minimize respondent
burden. In preliminary testing, respondents completed
the battery of tests in less than 15 minutes. At baseline
the research assistant administer the questionnaire with
the use of visual aids to help with answering the ques-
tions. When obtaining the consent, patients will be
informed of the follow up survey and the same research
assistant will contact the patients at six months. This
will help in establishing a rapport and increasing the
response rate at follow-up. The average retention rate
for the surveys conducted by the QOL research team at
our institution is in excess of 80%.
Quality control and data management
LIPS study collects a large number of data regarding
patient exposures and outcomes. To reduce measure-
ment error, a comprehensive data quality assurance pro-
gram will be employed. Data will be maintained on a
secure server with nightly back up. Single Mayo logon
LAN ID (local area network identification) provides
access to the data to authorized individuals. Electronic
range checks and validation rules will eliminate erro-
neous data entry and artifacts in numeric values. As an
independent quality controlm e a s u r ep e r i o d i ca u d i t so f
the database will be performed. Routine descriptive sta-
tistics will be obtained at regular intervals to assure
completeness of data collection.
Statistical Analysis
An estimate for the probability of ALI development will
be calculated for each patient based on the LIPS model.
Because of subjective nature of clinical definitions used
to identify the outcome of our study, it is necessary to
assess interobserver variability. Interobserver agreement
for ALI development will be assessed by calculating the
Kappa statistic, using a threshold of 0.6 as an indication
of acceptable interobserver agreement.
The calibration and discrimination of model will be
assessed using the Hosmer-Lemeshow goodness-of-fit
test and the receiver operating characteristic curve,
respectively. An area under the ROC curve greater than
80% will be considered to be the evidence of good
model discrimination. Using a LIPS cutpoint of 3.5 or
more identified in the preliminary data, the comparison
of the model prediction versus the actual event observed
will be summarized by a simple 2 by 2 table reporting
ALI propensity versus ALI development. Summary mea-
sures, based on the 2 by 2 table, will be reported: sensi-
tivity, specificity, positive predictive value, negative
predictive value, positive and negative likelihood ratios
along with their 95% confidence intervals.
In a matched case-control design the associations sug-
gested by preliminary clinical studies (Table 3) will be
compared between ALI cases and high risk controls pro-
pensity matched by age, gender and the probability of ALI
development at the time of hospital admission (LIPS, see
above). Subpopulation analyses will be performed to deter-
mine what hospital exposures are associated with ALI in
low/moderate ALI risk patients and what hospital expo-
sures factors are associated with no ALI development in
high ALI risk patients. The primary statistical endpoint is
the development of ALI at any time during hospital stay.
The matching is based on ALI risk at admission and the
exposure period at risk. For example, if a hospitalized
patient, who has an estimated propensity for developing
ALI of 20% actually develops ALI 10 hours after hospital
admission the exposures in matched control patient is
only measured during the initial 10 hours after hospital
admission. Paired statistics will be used for group compar-
isons. A conditional logistic regression model will be built
in the case of baseline imbalances.
The statistical endpoints for determining attributable
burden of ALI development in patients at risk are
unadjusted and quality adjusted survival after hospital
admission. All patients will be followed until death or
Table 4 Patient-reported outcome assessment.
Variable Instrument Time(s) of assessment
Quality of life SF-12 health survey 1. In hospital retrospective assessment of pre morbid QOL
2. 6 month follow up
Physical function Barthel Index 1. In hospital retrospective assessment of pre morbid QOL
2. 6 month follow up
Neuromuscular complications Overall neuropathy limitations scale 1. In hospital retrospective assessment of pre morbid QOL
2. 6 month follow up
Neurocognitive complications Folstein mini-mental status scale 1. In hospital retrospective assessment of pre morbid QOL
2. 6 month follow up
Neuropsychological
complications
1. Post-Traumatic Stress Syndrome (PTSS-10) (only at 6
months)
2. Yale depression scale
1. In hospital retrospective assessment of pre morbid QOL
2. 6 month follow up
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sored at the last date known to be alive. In addition,
we will assess which hospital exposures, impact the
long-term survival and quality-adjusted survival in
both ALI patients and high risk controls. We will use
Kaplan-Mayer survival curves to depict survival differ-
ences in these subgroups. In order to understand the
impact of ALI on quality of life, we will compare the l
quality of life measures between the ALI patients and
controls, taking into account the correlations between
serial (baseline and follow up) QOL measurements.
We will carry out quality-adjusted life years (QALY)
analyses to incorporate the QOL-related health state
utility variables into the survival analysis. We will com-
bine survival and quality of life using the time spent in
specific “health state” (ventilator, ICU, hospital, nur-
sing home, home) to describe the quality adjusted sur-
vival of ALI patients according to the following
formula:
QALY i  utility of health state i time patient spends in    *   health state i 
We expect that missing data will be minimized due to
the error checking capability of our data entry system.
We will handle missing data in a number of ways
including complete case analysis and imputation via
nearest neighbor, mean value, last value, and zero value
carried forward approaches. Multiple approaches are
used so that the sensitivity of results to alteration in
imputational assumptions may be assessed.
Sample size considerations
Planned enrollment of 500 ALI cases guarantee an ade-
quate sample size for LIPS validation. If we have 500
ALI cases and 80% score above the threshold for the
ALI model (sensitivity) then our precision will be .02
and the 95% CI would 0.78 to 0.82.
A comparison of 500 ALI cases with 500 propensity
matched high risk controls will allow us to determine
moderately high associations (odds ratio >2.0) between
common in-hospital exposures (prevalence >5%, i.e.
variability in fluid management, transfusion, antibiotics,
FIO2, mechanical ventilation) and ALI development
(Figure 3). We will be able to identify only strong asso-
ciations for less common in-hospital exposures (<5%).
Assuming a median survival of around 2 years in con-
trol population and ALI increases the risk of death by
about 1.25, then the study has 80% power to reject the
null hypothesis of equal survival of controls and ALI
patients. A target of 100 ALI survivors and 100 controls
assuming a standard deviation of the health related
quality of life score among ICU patients of 10 units, the
study has 80% power to detect a difference in self
reported quality of life of 4.0 units or greater.
Discussion
The LIPS study is a population based observational
cohort study that aims to identify patients at high risk
of developing ALI early in the course of illness (at the
time of hospital admission), and compare the in-hospital
(second hit) exposures and outcomes of patients at high
risk who do and do not develop ALI. Analysis and com-
parison of exposures and outcomes between patients at
high risk identified before ALI development is essential
to understand clinical pathogenesis of ALI and design
effective prevention strategies. By determining not only
candidate interventions, but also the attributable burden
of ALI, it will allow the prioritization of preventive stra-
tegies and future clinical trials.
Olmsted County offers a unique opportunity to study
potential ALI prevention targets in a geographically
defined population because all the critically ill patients
from the county are admitted to Mayo Clinic hospitals.
Figure 3 Power for a matched case control study of 500 ALI patients matched to 500 controls where the risk factor occurs at 10%,
5%, or 1% prevalence in the controls and the false positive rate is 0.05. As depicted, if 5% of the controls experience delayed fluid
resuscitation which increases the risk of ALI by 2 fold, then the study has about 82% power to reject the null hypothesis.
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bias common in clinical studies performed at tertiary care
institutions [23]. As a part of study design we have devel-
oped a near real time access to pertinent data in electronic
medical records to identify patients from the community
with or at high risk of ALI. The electronic infrastructure
will greatly facilitate to conduct this population based
study by minimizing study coordinator time necessary to
screen large number of patients. Time-sensitive biospeci-
men collection in a population of patients with strictly
defined phenotype and detailed capture of environmental
exposures will allow for the development of important
biospecimen repository for future collaborations in Gen-
ome Wide Association and plasma biomarker studies.
The principal limitation of our study is imposed by
the broad nature and definition of the primary outcome
of interest, ALI [21]. The exclusion of left atrial hyper-
tension poses a particular challenge in the clinical
assessment of ALI. In addition to using a standardized
definition and extensive training of study personnel, all
ALI cases will be reviewed by trained expert investiga-
tors. There is a possibility of ascertainment bias as we
will depend on the clinicians caring for the patient to
order the chest x-ray and the arterial blood gas neces-
sary to diagnose ALI. Fortunately, almost all patients
requiring respiratory support do have these tests per-
formed routinely every day. It is therefore extremely
unlikely that a significant ALI would occur without the
need to perform the chest x-ray and the arterial blood
gas as a part of clinical care.
Additional limitations of our approach come from the
observational design of this study. First, because partici-
pants are not randomly assigned to the exposures under
investigation, our study is particularly prone to indication
bias, in that patients receiving certain therapies may be
systematically different from those not receiving the thera-
pies. If these differences are associated with the outcome
of interest, the study results may be biased. Large sample
size and a comprehensive collection of exposure variables
will mitigate the potential bias by enabling our statisticians
to adjust for any measured factor found to predict the use
of each exposure under investigation. However, some
important factors may be unknown or unmeasured, result-
ing in residual confounding and bias. The population
based sample is clearly a strong point of our study. How-
ever, all patients will be treated in the two hospitals of the
single teaching medical center, and, although internal
validity will be high, the study results may not generalize
to patients in other settings. Moreover, we will not be able
to take advantage of additional variability in practice such
as would be possible in multicenter studies involving dif-
ferent parts of the world. Long study period raises another
question about whether the exposures, prognosis, and
incidence of ALI will be stable enough to allow the
proposed investigation. Fast pace changes in health care
delivery and quality improvement initiatives could plausi-
bly lead to the change in frequency of some of the pro-
posed in-hospital exposures. Should changes in practice
occur during the study period, our detailed observation of
both practice and outcomes will give us an opportunity to
correlate changes in practice with the development and
o u t c o m eo fA L Ia n dp o s s i b l yb ea b l et om a k es t r o n g e r
causal inferences from the observed associations.
This causal translational research study will not affect
the outcome of studied patients (this is a non-interven-
tion epidemiologic study) but will help in better under-
standing the clinical pathogenesis of ALI and the design
of future ALI prevention strategies. Since the therapeutic
options are limited once ALI develops, the prevention is
paramount. Unfortunately, effective prevention interven-
tions do not currently exist, and our knowledge about
clinical pathogenesis of ALI is limited. By identifying
patients at high risk earlier (in the emergency department
and operating room), and collecting biospecimens and
clinical data before ICU admission we hope to improve
our understanding of ALI and identify targets for future
quality improvement interventions and ALI prevention
trials. Previous studies have concentrated on patients in
the ICU with already established ALI. Hence the infer-
ences from these studies with regards to ALI pathogen-
esis and potential prevention targets are limited.
Potential future prevention strategies include, but are
not limited to 1) quality improvement interventions to
limit specific hospital acquired exposures (delayed treat-
ment of infection and shock, aspiration triggers, high
tidal volume ventilation, plasma transfusion from alloim-
munized donors), and 2) the use of systemic and inhaled
anticoagulants, antiplatelet agents, anti-inflammatory
drugs and antioxidants. Some of these therapies have
already been tested in preliminary clinical trials with
encouraging result. This is in contrast to uniformly nega-
tive results of mechanistic interventions when applied
later in the course of illness, once ALI is established.
Conclusion
This population based observational cohort study will
define 1) the population of patients at high risk for ALI
at the time of hospital admission 2) the most significant
second hit in-hospital exposures that may modify the
development and progression of ALI and 3) attributable
burden of ALI in the community. The results will
inform future mechanistic studies and clinical trials with
an ultimate goal of preventing this devastating complica-
tion of critical illness.
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